Acorda Therapeutics, Inc.
ACOR
Classificação em ações
#39148
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Preço da ação
$0.879
Última sincronização: 2024-05-07
Valor de mercado
$582.38K
Variação (1 dia)
9.88%
Variação (1 ano)
8,690.00%
País
US
Negociar Acorda Therapeutics, Inc. (ACOR)
Categoria
Healthcare
Receita da Acorda Therapeutics, Inc. (ACOR)
Receita em Mar 2024 TTM: $115.66M
De acordo com os últimos relatórios financeiros da Acorda Therapeutics, Inc., a receita atual da empresa (TTM) é $115.66M. Em 2022, a empresa obteve uma receita de $118.57M uma diminuição em relação a a receita do ano 2021, que foi de $129.07M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Acorda Therapeutics, Inc. de 2016 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $115.66M | -1.67% |
| 2023 | $117.63M | -0.79% |
| 2022 | $118.57M | -8.14% |
| 2021 | $129.07M | -15.62% |
| 2020 | $152.97M | -20.50% |
| 2019 | $192.41M | -59.19% |
| 2018 | $471.43M | -19.86% |
| 2017 | $588.29M | 13.22% |
| 2016 | $519.60M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 5,616.26% |
IN
|
